NasdaqGM:LGNDPharmaceuticals
Did Higher 2026 Guidance and XOMA Deal Just Shift Ligand Pharmaceuticals' (LGND) Investment Narrative?
Ligand Pharmaceuticals recently raised its 2026 revenue guidance to a range of US$270 million to US$310 million and discussed its planned acquisition of XOMA Royalty, while also participating in several investor conferences, including the H.C. Wainwright Royalty Company Virtual Conference on May 6, 2026.
This combination of higher guidance, an expanded royalty portfolio through the proposed XOMA Royalty acquisition, and active investor outreach could reshape how investors view Ligand’s...

